Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

MannKind Cuts Its Headcount, But Will It Matter?

By Todd Campbell - Oct 1, 2015 at 1:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

MannKind is laying-off workers to reduce expenses, but without sales growth these cuts may not be enough.

Source: MannKind

MannKind ( MNKD ) continues to cut its expenses in response to a slower-than-hoped ramp up in sales for its inhalable insulin Afrezza; however, the pace of cuts may not be steep enough to matter if sales don't begin to materialize soon.

Troubling launch

Leading up to its launch, expectations were sky-high for MannKind's Afrezza.

Afrezza, which is taken via a small inhaler prior to mealtime, offers an alternative to short-lasting insulin injections that led many people to conclude patients would flock to it once it became available this past February.

However, sales reported by its marketing partner Sanofi have been lackluster. In the first quarter, Sanofi reports just 1.1 million euros in Afrezza sales, and in the second quarter, Afrezza sales were about 2.2 million euros.

Bloated business

The anemic Afrezza sales have led to MannKind playing defense in order to protect the cash it received from Sanofi when Sanofi signed on to market Afrezza last year.

MannKind's latest lay-off comes on top of two prior lay-offs earlier in the year and while the number of people let go hasn't been reported by the company, seemingly untenable losses suggest that it's not a stretch to think that more employees could lose their jobs if sales don't pick up.

Despite cost savings programs shaving tens of millions of dollars in quarterly expenses in the past year, MannKind's operating expenses of $24.1 million still led to a loss of $28.9 million in the second quarter alone.

Source: MannKind

Financially troubling

Execution missteps in the company's bid to win FDA approval led to unexpected trial costs and spending associated with management's overly enthusiastic sales projections have saddled MannKind with a troubling balance sheet.

Ultimately, without a pick-up in sales, MannKind's $107 million in cash on the books may not be enough to make good on its swelling liabilities.

Removing the $170 million in deferred payments tied to its collaboration with Sanofi that, for accounting reasons, shows up under short-term liabilities, MannKind's total liabilities still total nearly $300 million, including about $170 million that is categorized as current.

Source: MannKind

This means that MannKind's current ratio, a quick-and-dirty calculation that shows how able a company is to make good on its short term obligations, is just 0.43, which is down from 0.66 earlier this year.

Can MannKind turn a corner?

Investors that remain optimistic over MannKind's future believe that sales should increase once more insurers ink favorable deals with the company that result in Afrezza getting placed on drug formularies.

Appearing on those formularies could reduce the burden on doctors and patients hoping to get approved for Afrezza reimbursement, in turn leading to prescription growth.

If so, then the next couple quarters will be critical. Typically, it can take six to nine months for a review that could result in permanent placement on a formulary, so those decisions are happening soon, if not already.

Looking ahead

A pickup in sales is critical to MannKind's survival given that it gave up 65% of the rights to Afrezza's profit (or loss) as part of its licensing deal with Sanofi. Also, MannKind's product losses on Afrezza are running at about $12 million per quarter and MannKind has been covering its share of those losses by borrowing the money from Sanofi. If Afrezza becomes profitable, MannKind will need to pay Sanofi back before any money tied to Afrezza before it can reward investors. If MannKind can't pay back Sanofi, then Sanofi can take over MannKind's pledged assets, which in turn could significantly impact the company.

"In the event of certain future defaults under the Sanofi Loan facility agreement for which the Company is not able to obtain waivers, the lender under the Sanofi Loan Facility may accelerate all of the Company's repayment obligations, and take control of the Company's pledged assets, potentially requiring the Company to renegotiate the terms of its indebtedness on terms less favorable to the Company, or to immediately cease operations" -- MannKind's second quarter 10-Q. 

If sales don't pick-up, then its unclear to me what the future will hold for the company. Sanofi has an option to exit its relationship with MannKind as early as next year, and although MannKind has said it's exploring the use of its inhalable technology for other medicine, it could be a long wait before any additional products make it to market. For those reasons, MannKind is far too risky of a bet for investors to own.


This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
$47.07 (-1.30%) $0.62
MannKind Corporation Stock Quote
MannKind Corporation

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/05/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.